Levosimendan Tillomed (Levosimendan)

• Levosimendan acts as an inodilator to improve cardiac output in severe heart failure states.
• Acute decompensated heart failure: improves contractility and reduces filling pressures, helping stabilize patients.
• Cardiogenic shock (off‑label): provides inotropic support when conventional agents are insufficient.
• Low cardiac output syndrome after cardiac surgery (off‑label): assists in restoring adequate systemic perfusion during postoperative recovery.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation, which reduces preload and afterload and improves overall cardiac output.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient blood pressure reduction.
• Nausea or vomiting: gastrointestinal discomfort.
• Tachycardia: increased heart rate.
• Dizziness: feeling of light‑headedness.
• Arrhythmias: occasional premature beats.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring intervention.
• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Liver enzyme elevation: increased transaminases indicating hepatic stress.
• Thrombocytopenia: reduced platelet count in rare cases.

• Before initiating levosimendan therapy, several safety considerations should be addressed.
• Monitor blood pressure: watch for hypotension, especially during the loading phase.
• Observe cardiac rhythm: continuous ECG monitoring for arrhythmias.
• Adjust dose in renal or hepatic impairment: reduce infusion rate if organ function is compromised.
• Avoid in severe hypotension: contraindicated when systolic pressure is markedly low.
• Use caution with concurrent vasodilators: may potentiate blood pressure decline.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines that affect cardiovascular dynamics or drug metabolism.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase levosimendan exposure.
• Other potent vasodilators (e.g., nitroprusside, high‑dose nitrates): risk severe hypotension.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic effect.
• ACE inhibitors or ARBs: additive blood pressure lowering.
• Diuretics: may exacerbate electrolyte shifts.
• Other inotropes (e.g., dobutamine): overlapping cardiac stimulation.
• Anticoagulants: monitor for bleeding if hypotension occurs.